Please login to the form below

Not currently logged in
Email:
Password:

Compassionate use programme

This page shows the latest Compassionate use programme news and features for those working in and with pharma, biotech and healthcare.

Daily brief: Novartis spends big on ezcema, Kite invests, another gene therapy IPO

Daily brief: Novartis spends big on ezcema, Kite invests, another gene therapy IPO

The company, based in London and New York, has four ongoing clinical programmes, one compassionate use programme and a broad pipeline of preclinical and research programmes.

Latest news

  • Roche’s Hemlibra first drug to top standard therapy in haemophilia A Roche’s Hemlibra first drug to top standard therapy in haemophilia A

    The two trials also back up the safety of Hemlibra, which became a matter of debate after some deaths were reported in patients taking it in trials or Roche’s compassionate ... use programme, which the company says were not linked to drug treatment.

  • Access to orphan drugs for rare cancers in EU28 Access to orphan drugs for rare cancers in EU28

    This article discusses one such early access programme called 'Compassionate use programme' in the EU28 which is in operation through set regulations and guidelines at European and national levels. ... Compassionate use programme. In recent times, early

  • ASH: Pfizer eyes re-launch of Mylotarg ASH: Pfizer eyes re-launch of Mylotarg

    Pfizer kept producing Mylotarg in order to make it available on compassionate use grounds in Europe and this has given independent investigators the opportunity to continue to study the drug. ... Meanwhile, Pfizer has said it will expand the compassionate

  • The seven letter debate that is Sovaldi The seven letter debate that is Sovaldi

    programme or registry that is clinician-driven and robust enough to provide reliable data. ... payer scheme that targets that group and/or sets up a compassionate use programme.

  • Oral hepatitis C regimens tackle advanced liver disease Oral hepatitis C regimens tackle advanced liver disease

    Merck recently started its phase III programme for the combination. Finally, Gilead reported the results of two phase II trials and data from a compassionate use programme which looked at the

More from news
Approximately 1 fully matching, plus 9 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Ashfield, part of UDG Healthcare plc, is a global leader in commercialisation services for the healthcare industry. We partner with...

Latest intelligence

2019: CRISPR and therapeutic gene editing comes of age
Can gene-editing deliver safe and effective therapeutics for patients with intractable diseases?...
The 10-year Web Challenge
Understanding your users’ needs is more critical online today than ever. A site should mould itself around these insights, deliver those needs quickly, efficiently and with plenty of white space....
Downloadable Pack: Understanding Multiple Sclerosis
Inside this downloadable pack, you’ll find a wealth of exclusive information on the way multiple sclerosis is commonly treated today. As well as areas of continuous improvement for the industry....

Infographics